Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  recurrent breast cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 173 for your search:
Start Over
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-302-02-02-03, NCI-2014-02093, NCT02213744
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-1301, NCI-2013-01418, 2012-004492-38, UTN U1111-1161-1603, NCT01808573
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: GBG78/BIG 1-13/NSABP-B-54-I, NCI-2014-02553, 2013-001040-62, NCT01864746
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PR-30-5010-C, NCI-2014-00678, 1307-BCG, 1307-BCG, BIG5-13, NCT01905592
Exemestane with or without Entinostat in Treating Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over, postmenopausal if female
Trial IDs: CBYL719C2301, NCI-2015-01171, 2015-000340-42, NCT02437318
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CP-MGAH22-04, NCI-2016-00295, NCT02492711
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-119, NCI-2016-00327, 153082, 2015-001020-27, NCT02555657
Weight Loss Interventions in Treating Overweight and Obese Women with a Higher Risk for Breast Cancer Recurrence
Status: Active
Phase: Phase III
Type: Behavioral study, Treatment
Age: 18 and over
Trial IDs: A011401, NCI-2015-01918, NCT02750826
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-355, NCI-2016-01555, 163422, 2016-001432-35, NCT02819518
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Imiquimod, Cyclophosphamide, and Radiation Therapy in Treating Patients with Breast Cancer with Skin Metastases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NYU 11-00598, NCI-2011-02879, NCT01421017
Multitargeted Tyrosine Kinase Inhibitor PLX3397 and Eribulin Mesylate in Treating Patients with Triple-Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12751, NCI-2015-01321, 141658, CC#12751, NCT01596751
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: X396-CLI-101, NCI-2012-01257, NCT01625234
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29642, NCI-2013-00898, 2014-004852-77, ARN-810-001, NCT01823835
Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C31001, NCI-2014-00386, NCT02049957
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARN-AR18-CT-101, NCI-2016-00136, NCT02052128
Ruxolitinib Phosphate and Trastuzumab in Treating Patients with Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM1906, NCI-2014-02015, NCT02066532
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2108, NCI-2014-01570, NCT02088684
Gemcitabine Hydrochloride, Trastuzumab, and Pertuzumab in Treating Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17656, NCI-2014-01935, 14.01.0062, 280513, ML28939, NCT02139358
Olaparib and mTOR Kinase Inhibitor AZD2014 or AKT Inhibitor AZD5363 in Treating Patients with Recurrent Endometrial, Triple Negative Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0784, NCI-2014-01973, NCT02208375
Start Over